Most Recent
A judge has dismissed a bid by former Murray Goulburn boss Gary Helou to push off mediation in an action brought by the ACCC, ruling that the ex-executive's trip to China was no reason to delay possible resolution of the case.
A federal judge on Friday set an August date to hear AMP's arguments for why competing class actions should be moved to the NSW Supreme Court, but ordered the company to alert the state court to the brewing jurisdictional battle.
AMP will begin its push on Friday to move competing Federal Court class actions to the NSW Supreme Court, but the company will face fierce opposition.
As the ACCC's criminal cartel case against ANZ, Citigroup and Deutsche Bank gets underway, the regulator will face off against a formidable team of lawyers with extensive experience in defending competition matters.
A judge has denied a bid for summary judgment by Garmin Australia in a lawsuit brought by the GPS giant seeking $1.1 million allegedly owed under an agreement to supply its products for sale in Australia.
Commonwealth Bank of Australia will pay $700 million to settle claims of lax anti-money laundering oversight.
AMP appeared in court Friday to defend the first of five class actions filed on behalf of shareholders in the wake of damaging Royal Commission hearings into its conduct over advice fees.
Two generic drug makers are fighting for access to confidential documents related to amendments by Neurim Pharmaceutical of patents covering its sleep drug Circadin, telling the Federal Court on Thursday privilege had been waived after a phone conversation between the company's founder and her lawyers from DLA Piper.
The judge overseeing a Maurice Blackburn-led shareholder class action against Commonwealth Bank of Australia over allegedly lax anti-money laundering and anti-terrorism financing controls has struck out a portion of the statement of claim for "pleading deficiencies".
A full bench of the Federal Court has dismissed an appeal by drug giant GlaxoSmithKline in a patent infringement case it brought over planned generic versions of its sustained-release Panadol.